Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence and prevalence of pancreatic cancer
3.2.1.2 Advancements in treatment modalities
3.2.1.3 Rising ageing population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Limited early detection
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.4.3 Asia Pacific
3.5 Reimbursement landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Exocrine pancreatic cancer
5.3 Endocrine pancreatic cancer
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Hormone therapy
6.6 Other treatment types
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Gender, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Male
8.3 Female
Chapter 9 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospitals
9.3 Oncology centers
9.4 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AstraZeneca
11.2 Bristol-Myers Squibb Company
11.3 Celgene Corporation
11.4 Eli Lilly and Company
11.5 Genentech (F. Hoffmann-La Roche Ltd.)
11.6 GlaxoSmithKline plc
11.7 Merck & Co., Inc.
11.8 Mylan N.V.
11.9 Novartis AG
11.10 PharmaCyte Biotech, Inc.
11.11 Pfizer, Inc.
11.12 Sanofi
11.13 Sun Pharmaceutical Industries Ltd.
11.14 Takeda Pharmaceutical Company Limited
11.15 Teva Pharmaceutical Industries Ltd.
